GARY YIM / SHUTTERSTOCK.COM
In 2015 the US Federal Circuit resolved the biosimilars case of Amgen v Sandoz. But the parties did not stop there, meaning the Supreme Court could potentially review it. LSIPR looks at the consequences of a possible review.
Signed into law by the Obama administration in 2009 and part of the Affordable Care Act, the Biologics Price Competition and Innovation Act (BPCIA) introduced a biosimilars pathway to the US. The new regulatory pathway brought with it a new problem: interpretation.
Two major items of interpretation of the BPCIA were brought to a head after a claim was brought against Zarxio, the first biosimilar product approved by the Food and Drug Administration (FDA).
In July last year the US Court of Appeals for the Federal Circuit sought to clarify rules on the ‘patent dance’ and the 180 days’ notice period for marketing a biosimilar in the case of Amgen v Sandoz.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Amgen v Sandoz, US Federal Circuit, US Supreme Court, Food and Drug Administration, biosimilar, Affordable Care Act, patent, patent dance, BPCIA,
